Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Sci-Tech Press Iceland.
Global Bioengineered Skin Substitutes Market To Reach $3.63 Billion By 2028 With A Growth Rate Of 13.6%
EIN Presswire
·
December 5, 2024
The Business Research Company’s Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only! LONDON, GREATER LONDON, UNITED KINGDOM, December 6, 2024 /EINPresswire.com/ -- The Business Research Company’s Early...
ASP Isotopes Inc. Completes Construction and Starts the Commissioning of Silicon-28 Enrichment Facility
GlobeNewswire, Inc.
·
November 26, 2024
- Construction of the Company’s Silicon-28 enrichment facility has been completed in line with previously communicated timelines. - Silicon-28 is an isotope that is believed to enable quantum computing and will likely improve the performance of...
CLARENDA “FARMER CEE” STANLEY WINS THE GOOD FARMER AWARD U.S. FROM DAVINES GROUP IN PARTNERSHIP WITH RODALE INSTITUTE
GlobeNewswire, Inc.
·
April 22, 2025
Kutztown, Penn., April 22, 2025 (GLOBE NEWSWIRE) -- This Earth Day, Davines Group and Rodale Institute are proud to announce Clarenda “Farmer Cee” Stanley as the first-ever recipient of The Good Farmer Award U.S. The award recognizes outstanding...
Renewable Energy Market to Grow CAGR of 8.61% by 2035 | Iberdrola, EDP Renewables, Tesla, Enel, First Solar
EIN Presswire
·
April 23, 2025
he Renewable Energy Market is witnessing significant trends as countries work towards reducing carbon emissions and increasing energy security. NEW YORK, NY, UNITED STATES, April 23, 2025 /EINPresswire.com/ -- As per MRFR analysis, the Renewable...
Oncopeptides expands on WODA partnership with addition of Africa and Eurasia to provide Pepaxti to Patients
GlobeNewswire, Inc.
·
September 4, 2024
ZURICH and ZUG, Switzerland and STOCKHOLM, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Veld Pharmaceuticals GmbH (“Veld”) and Slavpharma GmbH (“Slavpharma”) today...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
GlobeNewswire, Inc.
·
August 15, 2024
The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of...
Kefir Global Market Report 2024 Predicts High Growth Rate And Market Size Expansion
EIN Presswire
·
November 28, 2024
The Business Research Company’s Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only! LONDON, GREATER LONDON, UNITED KINGDOM, November 28, 2024 /EINPresswire.com/ -- The Business Research Company’s...
XPENG, futuristic leader of the Milan Design Week 2025
GlobeNewswire, Inc.
·
April 17, 2025
At the ADI Design Museum, the XPENG: #FUTUREMOBILITY exhibition, dedicated to innovation in intelligent mobility Italian preview for the XPENG P7+ electric sedan, the first car defined by Artificial Intelligence and XPENG AEROTH X2, the flying...
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
GlobeNewswire, Inc.
·
November 7, 2024
Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December 2024 Leadership team...
Oculis to Present at the Stifel 2024 Healthcare Conference
GlobeNewswire, Inc.
·
November 13, 2024
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be present at...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
GlobeNewswire, Inc.
·
October 22, 2024
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a...
Lactose Free Food Market Segments, Drivers, Restraints, And Trends For 2024-2033
EIN Presswire
·
November 11, 2024
The Business Research Company's Lactose Free Food Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033 LONDON, GREATER LONDON, UNITED KINGDOM, November 11, 2024 /EINPresswire.com/ -- The Business Research Company’s...
World's 20 Smartest Countries Revealed in Comprehensive New Study
EIN Presswire
·
November 26, 2024
First-ever analysis combines 40 years of data on degrees, patents, and research to rank global education leaders; small European nation takes top spot WASHINGTON, DC, UNITED STATES, November 26, 2024 /EINPresswire.com/ -- In a groundbreaking...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
GlobeNewswire, Inc.
·
October 22, 2024
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a...
Titan OS adds nine new channels in Europe in partnership with A+E Global Media™
EIN Presswire
·
April 24, 2025
This partnership expands Titan OS’ premium content offering with a variety of popular shows from its premium catalog, including Duck Dynasty... BARCELONA, SPAIN, April 24, 2025 /EINPresswire.com/ -- Titan OS S.L. (Titan OS), a European...
Gauzy’s and Journeo’s Strategic Partnership on Track to Enhance Road Safety on London’s Fleet of 8,500 Buses With Smart-Vision® Advanced Driver Assistance System (ADAS)
GlobeNewswire, Inc.
·
January 21, 2025
Gauzy’s ADAS technology now operational on over 2,500 buses in the U.K. capital city, reaching approximately 30% of the market Collaboration enables Gauzy to enter key European countries in Norway, Iceland, Sweden and Denmark Gauzy and Journeo are...
The U.S. Financial Regulatory Authority Officially Regulates SUP Miner: Launching a Safe, Efficient, and Risk-Free Free Bitcoin Cloud Mining Contract
GlobeNewswire, Inc.
·
October 31, 2024
Wilmington, Delaware, Oct. 31, 2024 (GLOBE NEWSWIRE) -- As cryptocurrency mining grows more complex and costly, SUP Miner’s cloud mining offers a practical and affordable solution for both new and experienced crypto enthusiasts. The Shift from...
VIVUS Announces Label Update for QSYMIA®
GlobeNewswire, Inc.
·
October 23, 2024
– QSYMIA® is the leading once-daily oral branded, weight-management medication – – First head-to-head randomized placebo-controlled study of QSYMIA® and phentermine demonstrating reductions in ambulatory blood pressure (ABPM) – – New label removes...
Norway, Poland Formalize New Agreement
MENAFN
·
April 23, 2025
(MENAFN) Norway and Poland have formalized a new agreement on Wednesday under the European Economic Area (EEA) and Norway Grants to promote economic and social progress in Poland while strengthening bilateral ties, according to a press release...
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
GlobeNewswire, Inc.
·
October 21, 2024
Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentum DIAMOND program committees expanded with globally renowned retina experts If approved, OCS-01 has the potential to...